Thymosin Alpha-1 (Tα1): Structure, Prothymosin Origin and TLR Signaling Research

Thymosin alpha-1 carries the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn, an acidic 28-residue chain that contains no cysteine and therefore forms no disulfide bond. PubChem CID 16130571 records the molecular formula C129H215N33O55, a molecular weight of 3108.3 g/mol and a monoisotopic mass of 3106.5041 Da.

Composition explains the peptide's behaviour in buffer. The chain carries six glutamate and three aspartate residues against only four lysines, with no arginine and no histidine, so at neutral pH the nine acidic side chains and the C-terminal carboxylate outweigh the basic ones. The N-terminal acetyl group removes the positive charge a free α-amino terminus would supply, pushing the net charge further negative and matching the isoelectric point reported near pH 4.0 to 4.3 by isoelectric focusing.

An unusual feature of the sequence is what it lacks. Thymosin alpha-1 contains no tryptophan, no tyrosine and no phenylalanine, so the molecule has no aromatic chromophore. PubChem computes an XLogP of -24, a topological polar surface area of 1460 Ų, 49 hydrogen bond donors, 59 acceptors and 111 rotatable bonds, describing a highly solvated, conformationally flexible chain with no lipophilic character and no fixed shape to preserve.

Thymosin alpha-1 arises inside cells as a proteolytic fragment rather than as an independent gene product. Sarandeses, Covelo, Díaz-Jullien and Freire reported in the Journal of Biological Chemistry in 2003 that mammalian legumain, a lysosomal asparaginyl endopeptidase, cleaves prothymosin alpha and releases the peptide from the parent chain.

The cleavage chemistry is specific. Legumain hydrolyses asparaginyl bonds, and in prothymosin alpha the enzyme was reported to cut at Asn28-Gly29 and at Asn35-Gly36 with comparable in-vitro efficiency. The first cut yields the 28-residue thymosin alpha-1; the second yields the 35-residue thymosin alpha-11. Both share the same acetylated N-terminus and differ only in how far the chain extends.

Prothymosin alpha itself is a 109-residue acidic nuclear protein associated with chromatin remodeling, and it is far more abundant in tissue than the 28-residue fragment. That relationship reframes what an assay measures, since circulating immunoreactive material historically attributed to thymosin alpha-1 overlaps with the intact precursor.

The molecule entered the literature well before its origin was understood. Goldstein and colleagues reported the isolation and sequence from bovine thymus fraction 5 in the Proceedings of the National Academy of Sciences in 1977. The acetyl group on serine 1 was part of that original assignment and remains the defining post-translational feature of the mature peptide.

Thymosin alpha-1 behaves as an intrinsically disordered peptide in aqueous solution, with no stable tertiary fold detected by nuclear magnetic resonance. Mandaliti, Nepravishta and co-workers reported in Amino Acids in 2016 that contact with negatively charged micelles and vesicles converts the disordered chain into two helical tracts separated by a flexible central break.

Anionic charge is the trigger rather than lipid bulk. Work published in Biochemistry in 2016 examined mixed dipalmitoylphosphatidylcholine and dipalmitoylphosphatidylserine bilayers by proton and natural-abundance nitrogen-15 NMR, and reported that association occurred when the bilayer exposed the anionic phosphatidylserine component. In a purely zwitterionic phosphatidylcholine surface the interaction was not observed, which makes exposed phosphatidylserine the reported structural recognition element.

Structural detail from the same series placed the acetyl group on serine 1 inserted into the membrane, with the N-terminal region spread out by the mobile central loop. That geometry gives the acetylation a physical role: a small hydrophobic cap on an otherwise strongly hydrophilic chain acts as the anchoring element at the interface.

A second finding from the Biochemistry report concerns carriage in solution. The C-terminal region was reported to associate with serum albumin, so in a serum-containing medium the peptide distributes between free and albumin-bound states. Since exposed phosphatidylserine marks apoptotic and stressed cell surfaces, an albumin carrier plus an anionic-surface recognition step is the structural picture the NMR literature offers for how a peptide with an XLogP of -24 reaches a membrane at all.

Thymosin alpha-1 acts on antigen-presenting cells through Toll-like receptor signaling across the mechanistic literature. Romani and colleagues reported in Blood in 2004 that the peptide drove maturation of murine and human dendritic cells with interleukin-12 production and a Th1-polarised antifungal response, and that the effect depended on Toll-like receptor signaling through the adaptor MyD88.

A second Blood paper from the same group in 2006 described the opposing arm of the same pathway. Thymosin alpha-1 induced indoleamine 2,3-dioxygenase expression in dendritic cells, activating tryptophan catabolism; the induction required TLR9 and signaling through the type I interferon receptor, and the downstream consequence was interleukin-10 production and generation of regulatory T cells. One molecule, in the same cell type, was reported to drive both a Th1-priming output and a tolerogenic output depending on receptor context.

Later work moved the receptor assignment to the endosomal single-stranded RNA sensor. Wei and colleagues reported in Cancer Research in 2022 that thymosin alpha-1 reversed M2 polarisation of tumour-associated macrophages during efferocytosis by activating SH2-containing inositol 5'-phosphatase 1 through a lysosomal TLR7 and MyD88 route, placing the peptide inside the endolysosomal compartment rather than at the plasma membrane.

A 2026 Cancer Research report from an overlapping group proposed a chaperone mechanism for that TLR7 step. Thymosin alpha-1 was reported to bind apoptotic bodies and shield apoptotic-body-borne miR-146a-5p from lysosomal RNase A, letting the microRNA reach and trigger TLR7 in dendritic cells. Circulating peptide levels fell after cytotoxic anticancer drug exposure in tumour-bearing mice, and resupplying it restored dendritic cell licensing in a TLR7-dependent manner.

Thymosin alpha-1 appears in recent preclinical work mainly as a modifier of myeloid and T-cell phenotype rather than as a direct antitumour agent. Liu and colleagues reported in Cell Reports Medicine in 2024 that type V adenovirus pushed tumour-associated macrophages toward an M2 phenotype and increased regulatory T-cell infiltration, and that the peptide reprogrammed those macrophages toward an antitumoural state.

A 2025 transcriptional study drew the same line more sharply. Solmonese and co-workers exposed cutaneous melanoma, glioblastoma and pleural mesothelioma cell lines, alongside CD4+ T, CD8+ T, B and natural killer cells from healthy donors, to thymosin alpha-1 for 48 hours and profiled the result by RNA sequencing. Differentially expressed genes in the cancer lines were minimal, while every immune subset responded and activated CD8+ T cells showed the largest transcriptional shift.

The 2026 in-vitro follow-up focused on that CD8+ compartment. Mishra and colleagues compared four conditions in human CD8+ T cells, namely untreated control, CD3/CD28 stimulation alone, peptide alone and the combination, and reported that the combination raised the proliferation index and elevated interleukin-2, interferon gamma, tumour necrosis factor alpha and interleukin-10, while the exhaustion markers PD-1, TIM-3 and LAG-3 fell.

An in-vivo counterpart appeared in the Journal of Gastroenterology and Hepatology in 2026. An orthotopic hepatocellular carcinoma model in aged mice of 22 to 26 months compared saline, interleukin-15, thymosin alpha-1 and the combination; the combined arm suppressed tumour growth, extended survival, lowered the senescent fraction of hepatic CD8+ T cells and raised granzyme B, perforin and interferon gamma.

A 2025 review in the International Journal of Molecular Sciences placed this body of work inside the biology of thymic involution, surveying reported effects on T-cell differentiation, thymic output, and dendritic cell and macrophage activity. The recurring description across these sources is a peptide that changes how immune cells are instructed rather than one acting on target tissue directly.

Thymosin alpha-1 was examined in the largest controlled human study reported for the molecule, the TESTS trial published in the BMJ in January 2025. The double-blind, placebo-controlled phase 3 trial enrolled 1106 adults aged 18 to 85 meeting sepsis-3 criteria across 22 centres in China between September 2016 and December 2020, randomly assigned 1:1 to peptide or placebo.

The primary result was null. Twenty-eight day all-cause mortality occurred in 127 of 552 participants (23.4%) in the peptide arm and 132 of 554 (24.1%) in the placebo arm, giving a hazard ratio of 0.99 with a 95% confidence interval of 0.77 to 1.27 and a log-rank P value of 0.93. No secondary outcome and no safety outcome differed significantly between the two arms.

That result sits against a background of smaller positive reports. Gu and colleagues published a systematic review and meta-analysis of randomised controlled trials in Frontiers in Cellular and Infection Microbiology in September 2025 covering the same indication. Pooled analyses of small trials and a single adequately powered trial can point in different directions, and TESTS is the larger and more rigorously controlled design.

For laboratory purposes the contrast is informative. Receptor-level and transcriptional activity in dendritic cells, macrophages and CD8+ T cells is documented and reproducible across independent groups, and it did not produce a mortality difference in a heterogeneous critical-care population. Mechanistic specificity and clinical outcome are separate questions, and the published record now contains clear data on both.

Thymosin alpha-1 is supplied as a lyophilized powder, and its computed profile matches that format: a PubChem XLogP of -24, a topological polar surface area of 1460 Ų and 49 hydrogen bond donors describe an extremely hydrophilic solid with essentially no lipophilic character. Published methods sections prepare working solutions in aqueous buffer or culture medium rather than in organic solvent.

Quantification by ultraviolet absorbance at 280 nm is unavailable for this peptide, because the 28-residue sequence contains no tryptophan, no tyrosine and no phenylalanine and therefore has no aromatic chromophore. Laboratories instead read peptide-bond absorbance near 214 nm, or use amino acid analysis, and this absence of an aromatic residue is a routine source of error when a protocol written for a different peptide is applied without adjustment.

Identity is confirmed by electrospray mass spectrometry. A 3108.3 g/mol chain ionises as a series of multiply charged species rather than a single protonated ion, with the triply and quadruply protonated forms falling near m/z 1037 and 778. Purity is reported by reversed-phase HPLC on the lot certificate of analysis, normally with an ion-pairing modifier such as trifluoroacetic acid in the mobile phase.

Lyophilized peptide material is normally kept frozen, protected from light and moisture, with aqueous stock solutions divided into aliquots so that repeated freeze-thaw cycles are avoided. One published finding bears on assay design: because the C-terminal region associates with serum albumin, the free fraction in a serum-containing medium differs from the nominal concentration added.

This material is offered for laboratory research use only. It is not a drug, not a food, and not intended for human or veterinary use.